Effect of lamivudine treatment on plasma levels of transforming growth factor β1, tissue inhibitor of metalloproteinases-1 and metalloproteinase-1 in patients with chronic hepatitis B

Figure 1 Correlation between plasma TGF-β₁ and TIMP-1 in patients with chronic hepatitis B treated with lamivudine.

Figure 2 Mean TGF-β₁ plasma concentrations before and dur-ing lamivudine therapy as well as 24 wk after its completion (wk 72) in respect to the final effect of the treatment. Statistical significance in comparison to normal values are indicated with asterisks and between groups with arrows.

Figure 3 Mean TIMP-1 plasma concentrations before and during lamivudine therapy as well as 24 wk after its completion (wk 72) in respect to the final effect of the treatment. Statistical significance in comparison to normal values are indicated with asterisks and between groups with arrows.

Figure 4 Mean MMP-1 plasma concentrations before and during lamivudine therapy as well as 24 wk after its completion (week 72) in respect to the final effect of the treatment. Statistical significance in comparison to normal values are indicated with asterisks and between groups with arrows.